Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 19/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14803224 | 0.87 | ANO1 (0.69) | ANO1ANO2 | |
| SCHEMBL14803630 | 0.86 | ANO1 (0.65) | ANO1ANO2 | |
| SCHEMBL3631114 | 0.85 | ANO1 (0.83) | ANO1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1954773 | 0.84 | ANO1 (0.65) | ANO1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1896682 | 0.84 | ANO1 (0.65) | ANO1ANO2 | |
| SCHEMBL1907415 | 0.82 | ANO1 (0.62) | ANO1ANO2 | |
| SCHEMBL1954048 | 0.82 | ANO1 (0.62) | ANO1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1908173 | 0.82 | ANO1 (0.61) | ANO1ANO2 | |
| SCHEMBL12314181 | 0.81 | ANO1 (0.67) | ANO1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13926174 | 0.81 | ANO1 (0.72) | ANO1ANO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8618307-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8394848-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8383670-B2 | Trisubstituted thiophenes that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2477982-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| CN-102256969-A | Compounds that modulate intracellular calcium | CALCIMEDICA INC | 2011-11-23 | — | — | CN | disclosed |
| US-20110212970-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110136816-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2321303-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7906553-B2 | Substituted thiophene modulators of intracellular calcium | CALCIMEDICA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010027875-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261725-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885KDM4E 4057/4885MEN1 2958/4885 |
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885KDM4E 4057/4885MEN1 2958/4885 |
| US-20110212970-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885KDM4E 4057/4885MEN1 2958/4885 |
| US-20130245025-A1 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | ANO1 114/4885KDM4E 4057/4885MEN1 2958/4885 |
| US-20110136816-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885KDM4E 4057/4885MEN1 2958/4885 |
| US-20110065724-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ANO1 114/4885KDM4E 4057/4885MEN1 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.